Are you over 18 and want to see adult content?
More Annotations
A complete backup of spotlightstories.co
Are you over 18 and want to see adult content?
A complete backup of ukecifras.com.br
Are you over 18 and want to see adult content?
A complete backup of mediakraina.biz.ua
Are you over 18 and want to see adult content?
A complete backup of whatismysign.net
Are you over 18 and want to see adult content?
A complete backup of curiosandosimpara.com
Are you over 18 and want to see adult content?
A complete backup of laurelmarshallcounseling.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of onlinefashion.com.hk
Are you over 18 and want to see adult content?
A complete backup of pitandquarry.com
Are you over 18 and want to see adult content?
A complete backup of cosmo-restaurants.co.uk
Are you over 18 and want to see adult content?
A complete backup of magichands.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of liebe-ohne-zwang.de
Are you over 18 and want to see adult content?
Text
more.
MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7 MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .CHOLANGIOCARCINOMA
Overview. NCI Definition: A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas.PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open), ARSENIC TRIOXIDE CAPSULE FORMULATION ORH 2014 An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7 MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .CHOLANGIOCARCINOMA
Overview. NCI Definition: A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas.PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open), ARSENIC TRIOXIDE CAPSULE FORMULATION ORH 2014 An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells KRAS G12V - MY CANCER GENOME KRAS G12V is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12V as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinicalsetting.
POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
MAP2K4 - MY CANCER GENOME MAP2K4 is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Squamous Cell Lung Carcinoma +.BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
KIT W557R - MY CANCER GENOME KIT W557R is a predictive biomarker for use of imatinib, dasatinib, nilotinib, sorafenib, and sunitinib in patients. Thymic carcinoma and melanoma have the most therapies targeted against KIT W557R or its related pathways . Dasatinib +. Thymic Carcinoma -. CLINICAL TRIAL: NCT04042480 NCT04042480. Description: This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
LRP1B - MY CANCER GENOME LRP1B is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains LRP1B status and malignant glioma as inclusion criteria, 1 is phase 1 (1 open) . Diffuse Glioma +. LRP1B is altered in 3.04% of diffuse glioma patients . WWW.MYCANCERGENOME.ORG www.mycancergenome.org HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS Q61K - MY CANCER GENOME Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and 7 have NCCN guidelines in at least one clinical setting.CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .ARID1A MUTATION
ARID1A Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain ARID1A Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Uveal Melanoma +.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting. CHEK1 - MY CANCER GENOME CHEK1 is an inclusion criterion in 3 clinical trials for soft tissue sarcoma, of which 2 are open and 1 is closed. Of the trials that contain CHEK1 status and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) . High Grade Ovarian Serous Adenocarcinoma +. AZD5305 - MY CANCER GENOME An orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway.NBN MUTATION
NBN Mutation is an inclusion criterion in 4 clinical trials for gastric adenocarcinoma, of which 4 are open and 0 are closed. Of the trials that contain NBN Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) . Pancreatic Carcinoma +. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) . CDKN2A - MY CANCER GENOME CDKN2A is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) . Appendix Carcinoma +. CDKN2A is altered in 0.66% of appendix carcinoma patients .ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
PALB2 MUTATION
PALB2 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PALB2 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (1 open) . Non-Hodgkin Lymphoma +. EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),ERBB2 R678Q
ERBB2 is altered in 1.84% of glioblastoma patients . ERBB2 R678Q is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 R678Q and glioblastoma as inclusion criteria, 1 is phase 2 (1 open) . WHO Grade III Glioma +. HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . AZD5305 - MY CANCER GENOME An orally bioavailable inhibitor of the nuclear enzyme poly (ADP-ribose) polymerase (PARP), with potential chemo/radiosensitizing and antineoplastic activities. Upon administration, PARP inhibitor AZD5305 selectively targets and binds to PARP and prevents PARP-mediated DNA repair of single-strand DNA breaks via the base-excision repair pathway. KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
ARSENIC TRIOXIDE CAPSULE FORMULATION ORH 2014 An orally bioavailable capsule formulation of the inorganic toxic compound arsenic trioxide (As2O3), with potential antineoplastic activity. Although the mechanism of action (MoA) of As2O3 is not well understood, upon oral administration of ORH 2014, As2O3 appears to bind to DNA, prevent DNA synthesis, and cause DNA fragmentation, which leads to an induction of apoptosis in proliferating cells HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
MODIFIED FOLFOX6 REGIMEN Modified folfox6 regimen has been investigated in 26 clinical trials, of which 22 are open and 4 are closed. NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .MYC OVEREXPRESSION
MYC Overexpression is an inclusion criterion in 2 clinical trials for double-hit lymphoma, of which 0 are open and 2 are closed. Of the trials that contain MYC Overexpression and double-hit lymphoma as inclusion criteria, 2 are phase 1 (0 open) . MYC is altered in 1.9% of multiple myeloma patients . KRAS A146T - MY CANCER GENOME Biomarker-Directed Therapies. KRAS A146T is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS A146T as a predictive biomarker, 2 are FDA-approved and 7ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),CHOLANGIOCARCINOMA
Overview. NCI Definition: A carcinoma that arises from the intrahepatic biliary tree (intrahepatic cholangiocarcinoma) or from the junction, or adjacent to the junction, of the right and left hepatic ducts (hilar cholangiocarcinoma). Grossly, the malignant lesions are solid, nodular, and grayish. Morphologically, the vast majority of cases are adenocarcinomas.JNJ-74856665
Jnj-74856665 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating jnj-74856665, 1 is phase 1 (1 open). Complex karyotype, Monosomy 7, and NPM1-MLF1 Fusion are the most frequent biomarker inclusion criteria for jnj-74856665 clinical trials. Myelodysplastic syndromes is the most common disease KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved andCCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .BERZOSERTIB
ATR kinase inhibitor VX-970 selectively inhibits ATR kinase activity and prevents ATR-mediated signaling in the ATR-checkpoint kinase 1 (Chk1) signaling pathway. This prevents DNA damage checkpoint activation, disrupts DNA damage repair, and induces tumor cell apoptosis. In addition, VX-970 sensitizes tumor cells to chemo- andradiotherapy.
EGFR L858R - MY CANCER GENOME EGFR L858R is a predictive biomarker for use of afatinib, erlotinib, gefitinib, osimertinib, capmatinib, crizotinib, dacomitinib, cetuximab, and pembrolizumab in patients. Of the therapies with EGFR L858R as a predictive biomarker, 6 are FDA-approved and 8 have NCCN guidelines in at least one clinical setting. EGFR EXON 21 MUTATION EGFR Exon 21 Mutation is an inclusion criterion in 8 clinical trials for non-small cell lung carcinoma, of which 8 are open and 0 are closed. Of the trials that contain EGFR Exon 21 Mutation and non-small cell lung carcinoma as inclusion criteria, 4 are phase 2 (4 open),CDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
KIT W557R - MY CANCER GENOME KIT W557R is a predictive biomarker for use of imatinib, dasatinib, nilotinib, sorafenib, and sunitinib in patients. Thymic carcinoma and melanoma have the most therapies targeted against KIT W557R or its related pathways . Dasatinib +. Thymic Carcinoma -. GSK3377794 - MY CANCER GENOME Gsk3377794 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating gsk3377794, 1 is phase 1/phase 2 (0 open) and 2 are phase 2 (2 open). CTAG1B Expression, HLA-A*02:01 Positive, and CTAG2 Expression are the most frequent biomarker inclusion criteria for gsk3377794 clinical trials. HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
BIOMARKER SEARCH
Biomarkers. About. Home. What Is My Cancer Genome? My Cancer Genome Data Sources. Legal Policies & Licensing RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related to cellular stress. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as intestinal cancerCDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
NRAS Q61K - MY CANCER GENOMEGENE MUTATION COLON CANCERNRAS Q61R THYROID CANCERDRIVER MUTATION LUNG CANCERNRAS MUTATIONS CANCERCOLORECTAL CANCER GENESCOLORECTAL CANCER SCREENING Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .ERBB2 L755_E757DEL
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 L755_E757del present in 0.01% of all breast carcinoma patients . ERBB2 L755_E757del is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755_E757del and breast carcinoma as inclusionERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
PTEN MUTATION (SOMATIC) PTEN Mutation (somatic) is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains PTEN Mutation (somatic) and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) . Colon Carcinoma +. PTEN is altered in 7.67% of colon carcinoma patients . HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
BIOMARKER SEARCH
Biomarkers. About. Home. What Is My Cancer Genome? My Cancer Genome Data Sources. Legal Policies & Licensing RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related to cellular stress. Missense mutations, nonsense mutations, silent mutations, and in-frame deletions are observed in cancers such as intestinal cancerCDKN2A D108Y
CDKN2A D108Y is an inclusion criterion in 2 clinical trials for glioblastoma, of which 1 is open and 1 is closed. Of the trials that contain CDKN2A D108Y and glioblastoma as inclusion criteria, 2 are phase 2 (1 open) . Head And Neck Squamous Cell Carcinoma +. CDKN2A is altered in 23.69% of head and neck squamous cell carcinomapatients
NRAS G12C - MY CANCER GENOME NRAS G12C is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS G12C and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) . Pancreatic DuctalAdenocarcinoma +.
NRAS Q61K - MY CANCER GENOMEGENE MUTATION COLON CANCERNRAS Q61R THYROID CANCERDRIVER MUTATION LUNG CANCERNRAS MUTATIONS CANCERCOLORECTAL CANCER GENESCOLORECTAL CANCER SCREENING Biomarker-Directed Therapies. NRAS Q61K is a predictive biomarker for use of binimetinib, cetuximab, and panitumumab in patients. Of the therapies with NRAS Q61K as a predictive biomarker, 2 are FDA-approved and 3 have NCCN guidelines in at least one clinical setting. IDH1 R132C - MY CANCER GENOME IDH1 is altered in 24.88% of glioma patients with IDH1 R132C present in 1.4% of all glioma patients . IDH1 R132C is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 R132C and glioma as inclusion criteria, 1 is phase 2 (1 open) .ERBB2 L755_E757DEL
ERBB2 is altered in 13.78% of breast carcinoma patients with ERBB2 L755_E757del present in 0.01% of all breast carcinoma patients . ERBB2 L755_E757del is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB2 L755_E757del and breast carcinoma as inclusionERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
PTEN MUTATION (SOMATIC) PTEN Mutation (somatic) is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains PTEN Mutation (somatic) and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) . Colon Carcinoma +. PTEN is altered in 7.67% of colon carcinoma patients . IDH1 - MY CANCER GENOME IDH1 is an inclusion criterion in 2 clinical trials for ependymoma, of which 2 are open and 0 are closed. Of the trials that contain IDH1 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) . Mixed Glioma +. IDH1 is altered in 85.53% of mixed glioma patients . MAPK1 - MY CANCER GENOME MAPK1 is an inclusion criterion in 4 clinical trials for melanoma, of which 4 are open and 0 are closed. Of the trials that contain MAPK1 status and melanoma as inclusion criteria, 2 are phase 1 (2 open) and 2 are phase 1/phase 2 (2 open) . MAPK1 is altered in 1.06% of non-hodgkin lymphoma patients .CCND1 MUTATION
CCND1 Mutation is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 Mutation and breast carcinoma as inclusion criteria, 1 is phase 2 (0 open) . Germ Cell Tumor +. CCND1 is altered in 0.14% of germ cell tumor patients .PIK3CA E545K
PIK3CA is altered in 13.98% of malignant solid tumor patients with PIK3CA E545K present in 2.86% of all malignant solid tumor patients . PIK3CA E545K is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA E545K and malignant solid tumor asinclusion
POLD1 - MY CANCER GENOME Polymerase (DNA directed), delta 1, catalytic subunit (POLD1) is a gene that encodes a subunit of DNA polymerase delta, a protein complex that plays a critical role in DNA replication and repair. Missense mutations, synonymous mutations, frameshift deletions, and nonsense mutations are observed in cancers such as colon cancer, skin cancer,and
KIT W557R - MY CANCER GENOME KIT W557R is a predictive biomarker for use of imatinib, dasatinib, nilotinib, sorafenib, and sunitinib in patients. Thymic carcinoma and melanoma have the most therapies targeted against KIT W557R or its related pathways . Dasatinib +. Thymic Carcinoma -.ERBB2 S310F
ERBB2 S310F is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 3 are open and 0 are closed. Of the trials that contain ERBB2 S310F and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) . UrethralCarcinoma +.
KRAS G12A - MY CANCER GENOME Biomarker-Directed Therapies. KRAS G12A is a predictive biomarker for use of afatinib, dacomitinib, erlotinib, gefitinib, osimertinib, cetuximab, and panitumumab in patients. Of the therapies with KRAS G12A as a predictive biomarker, 2 are FDA-approved and CLINICAL TRIAL: NCT04042480 NCT04042480. Description: This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. The study will have two parts. Part 1 of the study will find out how much SGN-CD228A should be given for treatment and how often. WWW.MYCANCERGENOME.ORG www.mycancergenome.org HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS Clinical Implications of Molecular Biomarkers. My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer.BIOMARKER SEARCH
Biomarkers. About. Home. What Is My Cancer Genome? My Cancer Genome Data Sources. Legal Policies & Licensing RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related toCDKN2A D108Y
CDKN2A D108Y is present in 0.06% of AACR GENIE cases, with lung adenocarcinoma, bladder urothelial carcinoma, squamous cell lung carcinoma, cholangiocarcinoma, and NRAS G12C - MY CANCER GENOME NRAS G12C is present in 0.10% of AACR GENIE cases, with colon adenocarcinoma, acute myeloid leukemia, endometrial endometrioid adenocarcinoma, melanoma, and cutaneous melanoma having the greatestprevalence .
IDH1 R132C - MY CANCER GENOME IDH1 R132C is present in 0.62% of AACR GENIE cases, with intrahepatic cholangiocarcinoma, acute myeloid leukemia, cutaneous melanoma, melanoma, and cholangiocarcinoma having the NRAS Q61K - MY CANCER GENOMEGENE MUTATION COLON CANCERNRAS Q61R THYROID CANCERDRIVER MUTATION LUNG CANCERNRAS MUTATIONS CANCERCOLORECTAL CANCER GENESCOLORECTAL CANCER SCREENING NRAS Q61K is present in 0.59% of AACR GENIE cases, with melanoma, cutaneous melanoma, colon adenocarcinoma, colorectal adenocarcinoma, and melanoma of unknown primary having theERBB2 L755_E757DEL
ERBB2 L755_E757del is present in 0.04% of AACR GENIE cases, with invasive breast carcinoma having the greatest prevalence . KIT W557R - MY CANCER GENOME KIT W557R is present in 0.05% of AACR GENIE cases, with gastrointestinal stromal tumor, anorectal melanoma, cutaneous melanoma, melanoma, and seminoma having the greatest prevalence . PTEN MUTATION (SOMATIC) AACR GENIE data is not categorized as somatic or germline. To see GENIE data for this alteration, click here. HOME - MY CANCER GENOMECLINICAL TRIALSDISEASESBIOMARKERSDRUGSPATHWAYSCONTRIBUTORS Clinical Implications of Molecular Biomarkers. My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer.BIOMARKER SEARCH
Biomarkers. About. Home. What Is My Cancer Genome? My Cancer Genome Data Sources. Legal Policies & Licensing RIT1 - MY CANCER GENOME Ras-like without CAAX 1 (RIT1) is a gene that encodes a protein that belongs to the Ras-related GTPases subfamily. The protein regulates p38 MAPK-dependent signaling cascades that are related toCDKN2A D108Y
CDKN2A D108Y is present in 0.06% of AACR GENIE cases, with lung adenocarcinoma, bladder urothelial carcinoma, squamous cell lung carcinoma, cholangiocarcinoma, and NRAS G12C - MY CANCER GENOME NRAS G12C is present in 0.10% of AACR GENIE cases, with colon adenocarcinoma, acute myeloid leukemia, endometrial endometrioid adenocarcinoma, melanoma, and cutaneous melanoma having the greatestprevalence .
IDH1 R132C - MY CANCER GENOME IDH1 R132C is present in 0.62% of AACR GENIE cases, with intrahepatic cholangiocarcinoma, acute myeloid leukemia, cutaneous melanoma, melanoma, and cholangiocarcinoma having the NRAS Q61K - MY CANCER GENOMEGENE MUTATION COLON CANCERNRAS Q61R THYROID CANCERDRIVER MUTATION LUNG CANCERNRAS MUTATIONS CANCERCOLORECTAL CANCER GENESCOLORECTAL CANCER SCREENING NRAS Q61K is present in 0.59% of AACR GENIE cases, with melanoma, cutaneous melanoma, colon adenocarcinoma, colorectal adenocarcinoma, and melanoma of unknown primary having theERBB2 L755_E757DEL
ERBB2 L755_E757del is present in 0.04% of AACR GENIE cases, with invasive breast carcinoma having the greatest prevalence . KIT W557R - MY CANCER GENOME KIT W557R is present in 0.05% of AACR GENIE cases, with gastrointestinal stromal tumor, anorectal melanoma, cutaneous melanoma, melanoma, and seminoma having the greatest prevalence . PTEN MUTATION (SOMATIC) AACR GENIE data is not categorized as somatic or germline. To see GENIE data for this alteration, click here. IDH1 - MY CANCER GENOME IDH1 (i socitrate dehydrogenase 1 (NADP+), soluble) encodes for the isocitrate dehydrogenase cytoplasmic protein, an epigenetic modifier. IDH1 is frequently mutated in glioma and acute myeloid leukemia, among other cancer types (PMID: 23558169).IDH1 is altered in 2.85% of all cancers with anaplastic astrocytoma, oligodendroglioma, astrocytoma, conventional glioblastoma multiforme, and MAPK1 - MY CANCER GENOME Mitogen-activated protein kinase 1 (MAPK1) is a gene that encodes a protein that belongs to the MAP kinase family. The protein functions in several cell signaling processes such as proliferation, differentiation, transcriptional regulation, and cellular development.CCND1 MUTATION
CCND1 Mutation is present in 0.62% of AACR GENIE cases, with endometrial endometrioid adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, endometrial carcinoma, and mantle cell lymphoma having the greatest prevalence .PIK3CA E545K
PIK3CA E545K is present in 2.61% of AACR GENIE cases, with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, bladder urothelial carcinoma, and breast invasive lobular carcinoma having the greatest prevalence . KRAS G12A - MY CANCER GENOME KRAS G12A is present in 0.75% of AACR GENIE cases, with lung adenocarcinoma, colon adenocarcinoma, colorectal adenocarcinoma, endometrial endometrioid adenocarcinoma, and rectal adenocarcinoma having the greatest prevalence . EGFR L858R - MY CANCER GENOME EGFR L858R is present in 1.12% of AACR GENIE cases, with lung adenocarcinoma, non-small cell lung carcinoma, small cell lung carcinoma, squamous cell lung KIT W557R - MY CANCER GENOME KIT W557R is present in 0.05% of AACR GENIE cases, with gastrointestinal stromal tumor, anorectal melanoma, cutaneous melanoma, melanoma, and seminoma having the greatest prevalence .ERBB2 S310F
ERBB2 S310F is present in 0.31% of AACR GENIE cases, with bladder urothelial carcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, rectal adenocarcinoma, and colon adenocarcinoma having the greatest prevalence . CLINICAL TRIAL: NCT04042480 This trial will study SGN-CD228A to find out whether it is an effective treatment for different kinds of cancer. It will also look at what side effects (unwanted effects) may occur. WWW.MYCANCERGENOME.ORG www.mycancergenome.orgCLINICAL TRIALS
DISEASES
BIOMARKERS
DRUGS
PATHWAYS
CLINICAL IMPLICATIONS OF MOLECULAR BIOMARKERS My Cancer Genome contains information on the clinical impact of molecular biomarkers in cancer-related genes, proteins, and other biomarker types on the use of anticancer therapies in cancer. This information is derived from FDA labels, NCCN and other professional society guidelines, clinical trials, peer-reviewed publications, andmore.
Learn About My Cancer Genome MOLECULAR MEDICINE RESOURCESTARGETED THERAPIES
Types, classification, and naming; FDA approved therapiesLearn More
MOLECULAR TESTING
Biomarkers can be detected using multiple types of testsLearn More
MOLECULAR TUMOR BOARD Molecular tumor board for patients with somatic or germline mutationsLearn More
GLOSSARY
Understand terms related to precision medicineLearn More
ABOUT
Home
What Is My Cancer Genome? My Cancer Genome Data Sources Legal Policies & Licensing Letter from the EditorsAcknowledgments
About GenomOncology
Contributors
How to Give to My Cancer GenomeMOLECULAR MEDICINE
Types of Molecular Tumor TestingCirculating DNA
Detecting Gene Alterations in CancersGlossary
Targeted Therapies
Molecular Tumor BoardCONTENT TYPES
Clinical Trials
Diseases
Biomarkers
Drugs
Pathways
My Cancer Genome is managed by the Vanderbilt-Ingram Cancer Center Copyright © 2010 - 2017 MY CANCER GENOMEDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0